Trastuzumab deruxtecan|1826843-81-5|(DS-8201; DS-8201a)-陌孚医药/Medlife

您当前的位置：

Trastuzumab deruxtecan (Synonyms: DS-8201; DS-8201a)

目录号: PL03733 纯度: ≥99%

CAS No. :1826843-81-5

商品编号	规格	价格	会员价
PL03733-1mg	1mg	¥7253.00	请登录
PL03733-5mg	5mg	询价	询价
PL03733-10mg	10mg	询价	询价
PL03733-50mg	50mg	询价	询价

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	Trastuzumab deruxtecan
英文名称	Trastuzumab deruxtecan
英文别名	Trastuzumab deruxtecan;Trastuzumab deruxtecan (solution)
Cas No.	1826843-81-5
包装储存	Please store the product under the recommended conditions in the Certificate of Analysis.

产品详情

Trastuzumab deruxtecan (DS-8201a) 是一种抗人表皮生长因子受体 2 (HER2) 抗体-药物偶联物 (ADC)。Trastuzumab deruxtecan 由人源化抗 HER2 抗体，酶促裂解的肽接头和拓扑异构酶 I 抑制剂组成。Trastuzumab deruxtecan 可用于 HER2 阳性乳腺癌和胃癌的研究。

生物活性

Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, and a topoisomerase I inhibitor. Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer.

性状

Solid

体外研究(In Vitro)

Trastuzumab deruxtecan (1 pM-10 nM; 5 days) inhibits the growth of HER2-positive KPL-4 cells, with an IC50 of 109.7 pM.
Trastuzumab deruxtecan (10 nM; 5 days) shows bystander killing effects in HER2-negative MDA-MB-468 cells. has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

Trastuzumab deruxtecan (3 mg/kg; a single i.v.) shows antitumor activity against not only HER2-positive tumors but also HER2-negative tumors under the co-inoculated condition.
Trastuzumab deruxtecan (10 mg/kg; i.v. on days 0 and 7) inhibits the tumor growth in in EMT6-hHER2 syngeneic mouse model. has not independently confirmed the accuracy of these methods. They are for reference only.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

ClinicalTrial

参考文献

[1]. Kotani D, et, al. Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer. Ther Adv Med Oncol. 2021 Jan 7;13:1758835920986518.
[2]. Ogitani Y, et, al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107(7):1039-46.

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation